Ralph Theo Schermuly Selected Research

Pulmonary Heart Disease (Cor Pulmonale)

3/2021	Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.
10/2005	Reversal of experimental pulmonary hypertension by PDGF inhibition.
4/2004	Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralph Theo Schermuly Research Topics

Disease

42	Pulmonary Hypertension 06/2020 - 04/2002
20	Vascular Remodeling 01/2021 - 04/2004
20	Hypoxia (Hypoxemia) 06/2020 - 03/2003
18	Pulmonary Arterial Hypertension 01/2021 - 04/2002
9	Cardiomegaly (Heart Hypertrophy) 01/2019 - 04/2004
9	Fibrosis (Cirrhosis) 01/2018 - 11/2009
6	Pulmonary Fibrosis (Fibrosing Alveolitis) 10/2015 - 10/2008
6	Neoplasms (Cancer) 01/2010 - 08/2005
5	Familial Primary Pulmonary Hypertension 01/2017 - 07/2005
4	Right Ventricular Hypertrophy 01/2021 - 01/2010
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 03/2011
4	Hypertrophy 01/2018 - 08/2007
3	Lung Neoplasms (Lung Cancer) 09/2021 - 11/2009
3	COVID-19 08/2021 - 01/2021
3	Pulmonary Heart Disease (Cor Pulmonale) 03/2021 - 04/2004
3	Emphysema 01/2019 - 03/2011
3	Body Weight (Weight, Body) 12/2018 - 06/2012
3	Heart Failure 08/2016 - 01/2015
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 08/2021 - 01/2021
2	Inflammation (Inflammations) 01/2021 - 04/2006
2	Heart Diseases (Heart Disease) 01/2020 - 08/2016
2	Cardiovascular Diseases (Cardiovascular Disease) 08/2015 - 01/2012
2	Lung Diseases (Lung Disease) 03/2014 - 11/2009
2	Idiopathic Pulmonary Fibrosis 01/2013 - 06/2011
2	Carcinoma (Carcinomatosis) 06/2007 - 03/2006
2	Hypotension (Low Blood Pressure) 04/2006 - 04/2006
1	Pulmonary edema of mountaineers 10/2021
1	Neoplasm Metastasis (Metastasis) 09/2021
1	Heart Neoplasms 01/2019
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 08/2016
1	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2015
1	Cardiomyopathies (Cardiomyopathy) 03/2015

Drug/Important Bio-Agent (IBA)

15	MonocrotalineIBA 06/2020 - 04/2004
10	Iloprost (Ventavis)FDA Link 01/2021 - 04/2002
10	Sildenafil Citrate (Viagra)FDA Link 01/2018 - 04/2002
7	Nitric Oxide (Nitrogen Monoxide)FDA Link 08/2015 - 03/2003
7	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2015 - 04/2004
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2005
6	Soluble Guanylyl CyclaseIBA 01/2018 - 01/2006
5	Semaxinib (SU5416)IBA 01/2019 - 01/2012
5	CollagenIBA 01/2018 - 11/2009
5	Imatinib Mesylate (Gleevec)FDA Link 01/2013 - 10/2005
4	Oxygen (Dioxygen)IBA 12/2018 - 08/2005
4	Phosphodiesterase 5 InhibitorsIBA 01/2018 - 10/2007
3	Vasodilator Agents (Vasodilators)IBA 03/2020 - 04/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2018 - 08/2005
3	riociguatIBA 01/2018 - 01/2012
3	Messenger RNA (mRNA)IBA 01/2018 - 08/2007
3	Fibronectins (Fibronectin)IBA 01/2018 - 11/2009
3	CytokinesIBA 11/2017 - 03/2006
3	Bleomycin (Blenoxane)FDA LinkGeneric 10/2015 - 11/2010
3	Chymases (Chymase)IBA 10/2015 - 01/2013
3	Platelet-Derived Growth FactorIBA 06/2012 - 01/2010
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 06/2012 - 10/2005
3	diethylstilbestrol monophosphate (PDES)IBA 02/2012 - 01/2010
3	tolafentrineIBA 03/2011 - 04/2004
3	ProstaglandinsIBA 02/2009 - 07/2005
3	treprostinil FDA Link 02/2009 - 10/2006
3	Epoprostenol (Prostacyclin)FDA LinkGeneric 10/2007 - 04/2002
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2018 - 01/2012
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2018 - 11/2017
2	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 09/2013
2	dironyl (terguride)IBA 01/2015 - 11/2010
2	SmokeIBA 01/2015 - 03/2011
2	Transcription Factors (Transcription Factor)IBA 11/2014 - 08/2005
2	Transforming Growth Factors (Transforming Growth Factor)IBA 09/2013 - 11/2009
2	Small Interfering RNA (siRNA)IBA 09/2013 - 04/2011
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2013 - 06/2011
2	Becaplermin (PDGF-BB)FDA Link 01/2013 - 04/2012
2	dimethylargininaseIBA 01/2013 - 06/2011
2	Phosphodiesterase InhibitorsIBA 01/2010 - 07/2005
2	Protein Isoforms (Isoforms)IBA 01/2010 - 11/2009
2	Vasoconstrictor AgentsIBA 10/2007 - 04/2006
2	15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidIBA 01/2006 - 07/2005
2	ThromboxanesIBA 01/2006 - 07/2005
1	Adenylate KinaseIBA 09/2021
1	Surface-Active Agents (Surfactants)IBA 08/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 03/2021
1	ChemokinesIBA 01/2021
1	ruxolitinibIBA 01/2021
1	Chemokine ReceptorsIBA 01/2021
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2019
1	6-chloropenicillanic acid S-sulfoxideIBA 01/2019
1	palbociclibIBA 01/2019
1	Atrial Natriuretic Factor (ANF)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 10/2016
1	WD repeat containing planar cell polarity effectorIBA 03/2015
1	Serotonin (5 Hydroxytryptamine)IBA 01/2015
1	piclamilastIBA 01/2015
1	N- (1- methyl- 5- indolyl)- N'- (3- methyl- 5- isothiazolyl)ureaIBA 01/2015
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 01/2015
1	5-HT2B Serotonin ReceptorIBA 01/2015
1	Tadalafil (Cialis)FDA Link 01/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2014

Therapy/Procedure

18	Therapeutics 10/2021 - 04/2002
2	Cardiac Catheters 02/2009 - 10/2008
2	Immunotherapy 06/2007 - 03/2006
1	Noninvasive Ventilation 08/2021